Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Adalimumab

Brand: Humira®
NICE TA: 455
Indication: Treating plaque psoriasis in children and young people (NICE TA455)
Disease category: Skin
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Adalimumab is recommended as an option for treating plaque psoriasis in children and young people aged 4 years or older, only if the disease:

•is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
•has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated.

Stop adalimumab treatment at 16 weeks, if the psoriasis has not responded adequately. An adequate response is defined as a 75% reduction in the PASI score from the start of treatment.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red